直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Federal Circuit Reaffirms Burdens of Proof Between IPR and District Court

November 3, 2025

Authored and Edited by Wyatt L. Bazrod; Erik R. Puknys; Xu Wang*

In Inland Diamond Products Co. v. Cherry Optical Inc., No. 2024-1106 (Fed. Cir. Oct. 15, 2025), the Federal Circuit determined the district court’s grant of summary judgment based on issue preclusion was improper, vacating the decision and remanding the case.

In 2019, the PTAB determined certain claims of Inland Diamond Products’ patents were unpatentable in an IPR. This determination was never appealed to the Federal Circuit. Inland subsequently filed suit against Cherry Optical and asserted claims, all of which depend from claims the Board determined were unpatentable. On summary judgment, the district court ruled issue preclusion applied to limitations previously found unpatentable, and considered only the remaining limitations before ruling the asserted claims were invalid as obvious.

On appeal, the Federal Circuit reversed and remanded, reaffirming the principle that issue preclusion may not apply to issues raised in a subsequent proceeding that applies a different legal standard from the original proceeding. In the IPR context, because the Board’s findings were reached under a lower standard of proof (i.e., preponderance of the evidence), the Federal Circuit held that there could be no issue-preclusive effect in district court invalidity proceedings, where facts must be proven under a higher standard of proof (i.e., clear and convincing evidence). The Court clarified that the district court also erred in reasoning that Inland could defend the asserted claims only because they had been adjudicated as not unpatentable in the IPR. The Court explained that issue preclusion does not attach where the claims were never determined invalid through any Federal Circuit appeal.

Tags

estoppel

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Contacts

Wyatt L. Bazrod
Associate
Atlanta, GA
+1 404 653 6518
Email
Erik R. Puknys
Partner
Palo Alto, CA
+1 650 849 6644
Email

*Xu Wang is a Law Clerk at Finnegan. 

Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP